TTNP - Titan Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.1748
+0.0085 (+5.11%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.1663
Open0.1740
Bid0.1900 x 1000
Ask0.1901 x 1400
Day's Range0.1711 - 0.1870
52 Week Range0.1600 - 3.7800
Volume9,881,613
Avg. Volume1,719,068
Market Cap2.517M
Beta (3Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-0.9280
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.95
Trade prices are not sourced from all markets
  • American City Business Journals

    These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year

    While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?

  • Titan Pharmaceuticals Announces Pricing Of $9.0 Million Underwritten Public Offering
    PR Newswire

    Titan Pharmaceuticals Announces Pricing Of $9.0 Million Underwritten Public Offering

    SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced the pricing of an underwritten public offering of 40,000,000 units at a price to the public of $0.225 per unit. Each unit issued in the offering consists of one share of common stock (or pre-funded warrant in lieu thereof) and one Class B Warrant to purchase one share of common stock. The Class B Warrants will be immediately exercisable at a price of $0.225 per share of common stock and will expire five years from the date of issuance.

  • Titan Pharmaceuticals and Crossroads of Southern Nevada Announce Probuphine® Availability at Crossroads Rehabilitation Facilities
    PR Newswire

    Titan Pharmaceuticals and Crossroads of Southern Nevada Announce Probuphine® Availability at Crossroads Rehabilitation Facilities

    SOUTH SAN FRANCISCO, Calif., Oct. 1, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) and Crossroads of Southern Nevada ("Crossroads") rehabilitation facility today announced that Crossroads has healthcare providers who are specially trained in the insertion and removal of Probuphine® (buprenorphine) implants, and will now offer Probuphine for use in eligible patients with Opioid Use Disorder (OUD). Based in Las Vegas, Crossroads is a drug and alcohol rehabilitation center licensed by the State of Nevada and its Substance Abuse Prevention and Treatment Agency (SAPTA). "We are excited that Crossroads is implementing Probuphine as part of their comprehensive OUD treatment program," said Titan's Executive Vice President and Chief Commercial Officer, Dane Hallberg.

  • Titan Receives Approval For Second Year Of NIDA Grant Funding For Development Of A Nalmefene Implant
    PR Newswire

    Titan Receives Approval For Second Year Of NIDA Grant Funding For Development Of A Nalmefene Implant

    SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 /PRNewswire/ -- National Institutes of Health's National Institute on Drug Abuse (NIDA) has approved approximately $6.1 million in second-year funding for Titan's non-clinical development of a ProNeura™ based six-month implantable formulation of Nalmefene, an opioid antagonist, intended for the prevention of relapse to opioid addiction, following opioid detoxification. NIDA awarded Titan a two-year grant in the amount of $6.7 million in September 2018 for the project, subject to satisfactory project progress, fund availability and certain other conditions. As a result of a change in the grant award terms regarding company matching funds, the second-year award covers both the Federal and company match amounts of the original year two award, thereby increasing the aggregate potential expense reimbursement to approximately $8.7 million.

  • Thomson Reuters StreetEvents

    Edited Transcript of TTNP earnings conference call or presentation 14-Aug-19 8:30pm GMT

    Q2 2019 Titan Pharmaceuticals Inc Earnings Call

  • Zacks Small Cap Research

    TTNP: Long on Opportunity, Short on Capital

    Despite several factors in its favor including global expansion and repeat patients, second quarter revenues for Titan Pharmaceuticals, Inc. (TTNP) disappointed and missed our modest growth estimates. Despite an opioid epidemic where almost 70,000 people1 are dying annually, and two million2 are addicted in the United States, sales have languished at around $300,000, despite entering the third year of approval for the ProNeura implant. Titan has taken several steps to advance the commercialization of Probuphine, forging partnerships with AllianceRx to help with payors and fulfillment, with AppianRx to provide patient support and with Accredo for product inventory management, billing and payment as well as deep relationships with third party payors.

  • Some Titan Pharmaceuticals (NASDAQ:TTNP) Shareholders Have Copped A 99% Share Price Wipe Out
    Simply Wall St.

    Some Titan Pharmaceuticals (NASDAQ:TTNP) Shareholders Have Copped A 99% Share Price Wipe Out

    Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So...

  • Benzinga

    The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 15) Novocure Ltd (NASDAQ: NVCR ) Down In The Dumps (Biotech ...

  • Titan Pharmaceuticals Reports Second Quarter 2019 Financial Results
    PR Newswire

    Titan Pharmaceuticals Reports Second Quarter 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif. , Aug. 14, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported financial results for the second quarter ended June 30, 2019 and provided an update ...

  • Benzinga

    Q2 Earnings Preview For Titan Pharmaceuticals

    On Wednesday, August 14, Titan Pharmaceuticals (NASDAQ: TTNP ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue Wall Street analysts see Titan ...

  • Titan Pharmaceuticals To Release Second Quarter 2019 Financial Results On August 14 - Conference Call To Follow
    PR Newswire

    Titan Pharmaceuticals To Release Second Quarter 2019 Financial Results On August 14 - Conference Call To Follow

    SOUTH SAN FRANCISCO, Calif. , Aug. 9, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) will announce its second quarter 2019 financial results after market close on Wednesday, August 14, ...

  • Titan Pharmaceuticals Announces Pricing Of $2.1 Million Registered Direct Offering
    PR Newswire

    Titan Pharmaceuticals Announces Pricing Of $2.1 Million Registered Direct Offering

    SOUTH SAN FRANCISCO, Calif., Aug. 7, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced it has entered into a securities purchase agreement with a single accredited institutional investor to purchase approximately $2.1 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and each warrant will be $0.75. Under the terms of the purchase agreement, Titan has agreed to sell 2,852,314 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof).

  • Titan Pharmaceuticals Expands Patient Access To Probuphine® Via Specialty Product Distribution Agreement With CVS Caremark
    PR Newswire

    Titan Pharmaceuticals Expands Patient Access To Probuphine® Via Specialty Product Distribution Agreement With CVS Caremark

    SOUTH SAN FRANCISCO, Calif., July 9, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that it has executed a specialty product distribution agreement with CVS Caremark, a subsidiary of CVS Health, further expanding access to treatment with Probuphine (buprenorphine) implant, Titan's novel maintenance treatment for Opioid Use Disorder (OUD) in eligible patients. Titan expects the majority of Probuphine sales in the United States to be through the specialty pharmacy distribution model and expansion of its specialty pharmacy network is a key component of a commercial strategy aimed at facilitating patient access to treatment by streamlining the product ordering and fulfillment process.

  • What Does Titan Pharmaceuticals, Inc.'s (NASDAQ:TTNP) Balance Sheet Tell Us About It?
    Simply Wall St.

    What Does Titan Pharmaceuticals, Inc.'s (NASDAQ:TTNP) Balance Sheet Tell Us About It?

    Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is a small-cap stock with a market capitalization of US$17m. While investors...

  • Titan Pharmaceuticals And Molteni Receive European Regulatory Approval For Probuphine
    PR Newswire

    Titan Pharmaceuticals And Molteni Receive European Regulatory Approval For Probuphine

    SOUTH SAN FRANCISCO, Calif., June 26, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that the European Commission ("EC") has approved Sixmo®-buprenorphine, the brand name for Probuphine® (buprenorphine) implant in the European Union ("EU"). The EC's decision, received today by Molteni, applies to all 28 EU member states, where Sixmo is now approved for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.

  • Titan Pharmaceuticals Partners With Southside To Further Expand Specialty Pharmacy Network For Probuphine®
    PR Newswire

    Titan Pharmaceuticals Partners With Southside To Further Expand Specialty Pharmacy Network For Probuphine®

    SOUTH SAN FRANCISCO, Calif., June 4, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that it has executed a pharmacy services agreement with Southside Specialty Pharmacy, further expanding access to treatment with Probuphine (buprenorphine) implant, Titan's novel maintenance treatment for Opioid Use Disorder (OUD) in eligible patients. "We are looking forward to working with Titan to provide patients with a unique, long-term maintenance treatment option for OUD," said Southside's Chief Executive Officer, Amit Jain.

  • Zacks Small Cap Research

    TTNP: A+ Partnerships: AllianceRx, AppianRx & Accredo

    Several important events took place in the first quarter of 2019 for Titan Pharmaceuticals, Inc. (TTNP) which were reported in the May 15th press release and in a concurrently filed 10-Q. During the quarter, Titan recorded total revenues of $0.9 million compared to $1.1 million in comparable period last year. Highlights for the first quarter and year to date include partnerships with AllianceRx Walgreens Prime, AppianRx and Accredo specialty pharmacy.

  • Thomson Reuters StreetEvents

    Edited Transcript of TTNP earnings conference call or presentation 15-May-19 8:30pm GMT

    Q1 2019 Titan Pharmaceuticals Inc Earnings Call

  • Associated Press

    Titan Pharmaceuticals: 1Q Earnings Snapshot

    On a per-share basis, the San Francisco-based company said it had a loss of 34 cents. The specialty pharmaceutical company posted revenue of $945,000 in the period. In the final minutes of trading on Wednesday, ...

  • Titan Pharmaceuticals Reports First Quarter 2019 Financial Results
    PR Newswire

    Titan Pharmaceuticals Reports First Quarter 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif. , May 15, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported financial results for the first quarter ended March 31, 2019 and provided an update ...

  • Titan Pharmaceuticals Further Expands Patient Access To Probuphine® Via Product Purchase And Supply Agreement With Express Scripts' Specialty Pharmacy, Accredo®
    PR Newswire

    Titan Pharmaceuticals Further Expands Patient Access To Probuphine® Via Product Purchase And Supply Agreement With Express Scripts' Specialty Pharmacy, Accredo®

    Titan expects the majority of Probuphine sales in the United States to be through the specialty pharmacy distribution model, where a specialty pharmacy carries inventory, directly handles the subsequent patients' insurance billing and payment processes, and ships to the healthcare provider as prescribed. This system is designed to facilitate patient access to treatment by streamlining the product ordering and fulfillment process for healthcare providers and their staff.  In February 2019, Titan announced a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime.

  • Titan Pharmaceuticals To Release First Quarter 2019 Financial Results On May 15 - Conference Call To Follow
    PR Newswire

    Titan Pharmaceuticals To Release First Quarter 2019 Financial Results On May 15 - Conference Call To Follow

    SOUTH SAN FRANCISCO, Calif. , May 8, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) will announce its first quarter 2019 financial results after market close on Wednesday, May 15, 2019 ...

  • Thomson Reuters StreetEvents

    Edited Transcript of TTNP earnings conference call or presentation 2-Apr-19 12:30pm GMT

    Q4 2018 Titan Pharmaceuticals Inc Earnings Call

  • Titan Pharmaceuticals And Molteni Announce Positive EU CHMP Opinion For Probuphine®
    PR Newswire

    Titan Pharmaceuticals And Molteni Announce Positive EU CHMP Opinion For Probuphine®

    SOUTH SAN FRANCISCO, Calif., April 29, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has adopted a positive opinion recommending the granting of a marketing authorization for the medicinal product Sixmo, the brand name for Probuphine (buprenorphine) implant in the European Union ("EU"). Sixmo is indicated for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.

  • GlobeNewswire

    Knight Therapeutics: Use of PROBUPHINE™ for Opioid Disorder Gains Momentum Across Canada; Subdermal Implant Now in Use from Coast to Coast

    Knight Therapeutics Inc. (GUD.TO) ("Knight"), a Canadian specialty pharmaceutical company, is pleased to announce that PROBUPHINE™, a new treatment in the fight against opioid addiction, is now being implanted in patients across the country. Approved by Health Canada in April 2018, PROBUPHINE™ is the only subdermal implant designed to deliver buprenorphine continuously for 6 months following a single treatment.